Insider Selling: Foamix Pharmaceuticals Ltd (FOMX) Insider Sells 5,000 Shares of Stock

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) insider Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock in a transaction on Monday, January 8th. The shares were sold at an average price of $6.17, for a total value of $30,850.00. Following the completion of the transaction, the insider now owns 16,271 shares in the company, valued at $100,392.07. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Meir Eini also recently made the following trade(s):

  • On Wednesday, January 10th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.05, for a total value of $30,250.00.
  • On Thursday, January 4th, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.68, for a total value of $33,400.00.
  • On Tuesday, January 2nd, Meir Eini sold 5,000 shares of Foamix Pharmaceuticals stock. The shares were sold at an average price of $6.18, for a total value of $30,900.00.

Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) traded down $0.06 during mid-day trading on Friday, reaching $6.34. The company had a trading volume of 20,383 shares, compared to its average volume of 94,934. Foamix Pharmaceuticals Ltd has a 1 year low of $4.03 and a 1 year high of $11.11. The stock has a market cap of $237.33, a P/E ratio of -4.84 and a beta of 1.62.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative return on equity of 54.81% and a negative net margin of 1,439.32%. The business had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $0.90 million. During the same quarter last year, the firm earned ($0.19) earnings per share. The firm’s quarterly revenue was down 64.6% compared to the same quarter last year. research analysts predict that Foamix Pharmaceuticals Ltd will post -1.35 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in FOMX. Wells Fargo & Company MN grew its stake in Foamix Pharmaceuticals by 1,738.5% during the 3rd quarter. Wells Fargo & Company MN now owns 47,801 shares of the specialty pharmaceutical company’s stock worth $265,000 after buying an additional 45,201 shares during the last quarter. PDT Partners LLC purchased a new position in Foamix Pharmaceuticals during the 2nd quarter worth $304,000. UBS Asset Management Americas Inc. grew its stake in Foamix Pharmaceuticals by 1.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock worth $493,000 after buying an additional 1,633 shares during the last quarter. DAFNA Capital Management LLC grew its stake in Foamix Pharmaceuticals by 9.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock worth $1,650,000 after buying an additional 30,000 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Foamix Pharmaceuticals by 38.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after buying an additional 151,849 shares during the last quarter. Hedge funds and other institutional investors own 57.43% of the company’s stock.

A number of research analysts have recently issued reports on FOMX shares. HC Wainwright set a $12.00 price target on Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 29th. Guggenheim started coverage on Foamix Pharmaceuticals in a report on Tuesday, December 5th. They issued a “buy” rating and a $8.00 price target on the stock. Finally, Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th.

TRADEMARK VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2018/01/19/insider-selling-foamix-pharmaceuticals-ltd-fomx-insider-sells-5000-shares-of-stock.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit